The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

Klebsiella pneumoniae carbapenemase (KPC) variants, which refer to the substitution,
insertion, or deletion of amino acid sequence compared to wild bla KPC type, have reduced …

First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have
encountered a worldwide success, particularly in K. pneumoniae isolates. These beta …

The antibacterial agents currently in clinical development are predominantly derivatives of
well-established antibiotic classes and were selected to address the class-specific …

The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in
critically ill patients presents many challenges. Since an effective treatment should be …

Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread
and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained …

Abstract Objective Ceftazidime–avibactam (CAZ-AVI) is a novel synthetic β-lactamase
inhibitor combination. Although the combination has been available clinically for only a few …

Background Carbapenem resistance is defined as in vitro non-susceptibility to any
carbapenem and/or documented production of a carbapenemase. This feature has rapidly …

Objectives The aim was to investigate the activity of ceftazidime/avibactam (CAZ/AVI)
against carbapenem-resistant Klebsiella pneumoniae (CRKP) and identify the resistance …

As a class, the b-lactams are the most commonly prescribed and clinically dependable
antimicrobials in the United States, representing more than 65% of injected antibiotic …